Showing results (11-20 of 42) with videos related to
Sort By:
Pageof 5
Clinical Lung Cancer|January 2, 2013
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomographySilvia Novello, Tiziana Vavalà, Matteo Giaj Levra, et al.Bulletin Du Cancer|October 9, 2020
Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patientsElisa Gobbini, Julie Charles, Anne-Claire Toffart, et al.Targeted Oncology|January 29, 2013
Clinical meta-analyses of targeted therapies in adenocarcinomaEmilio Bria, Maria Bonomi, Sara Pilotto, et al.Clinical Lung Cancer|August 8, 2012
Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using low-dose spiral computed tomographyAdriano M Priola, Sandro M Priola, Matteo Giaj-Levra, et al.Frontiers in Medicine|November 19, 2019
Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized MedicineJulian Pinsolle, Anne McLeer-Florin, Matteo Giaj Levra, et al.JTO Clinical and Research Reports|January 23, 2023
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European SurveyMarco Tagliamento, Jordi Remon, Matteo Giaj Levra, et al.Journal of Medical Case Reports|July 7, 2017
Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case reportHélène Pluchart, Julian Pinsolle, Julien Cohen, et al.Cancers|October 29, 2020
Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung CancerElisa Gobbini, Aurélie Swalduz, Matteo Giaj Levra, et al.Cancer Immunology, Immunotherapy : CII|November 25, 2021
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective studyGeoffroy Bilger, Nicolas Girard, Hélène Doubre, et al.Lung Cancer (Amsterdam, Netherlands)|July 13, 2015
Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective studyCinzia Ferrero, Serena Badellino, Andrea Riccardo Filippi, et al.Pageof 5